Professor Jean-Yves Blay begins a new chapter in his commitment to the fight against cancer. Renewed for a third term at the head of the Léon Bérard Center (CLB), located in Lyon, this renowned oncologist and researcher continues to uphold the ambitions of this institution of excellence, in the heart of the Auvergne-Rhône-Alpes region.
Summary & quick access
Toggle
A remarkable journey at the Léon Bérard Center
General Director of CLB since December 1, 2014, Jean-Yves Blay has left his mark on the management of this flagship establishment dedicated to the fight against cancer. Under his leadership, the Léon Bérard Center has established itself as a key player in cancer research and innovation. The renewal of his mandate for five additional years, formalized by ministerial decree on October 31, demonstrates the confidence of public authorities in his ability to continue to lead this establishment to new heights. THE Léon Bérard Center is not only recognized for its medical expertise, but also for its patient-centered, multidisciplinary approach. Through international collaborations and investments in research, it has become a reference in the treatment and understanding of complex cancers, particularly sarcomas.
An internationally renowned expert
Jean-Yves Blay is not only a talented administrator. He is also a medical oncologist and researcher whose expertise is recognized around the world. His work in the treatment of sarcomas, rare cancers affecting connective tissues, has earned him international recognition. His presence in the Clarivate 2024 ranking of the world’s most cited researcherswhich lists the scientists who have had the most impact in their field, bears witness to this. This distinction, known as “Highly Cited Researchers”, highlights its major role in medical research. Few French oncology researchers appear on this list, which further reinforces the singularity of his career.
Leadership beyond local borders
Beyond his responsibilities at the Léon Bérard Center, Jean-Yves Blay plays a central role in the French and international oncological landscape. Since October 2019, he has chaired Unicancerthe network bringing together all French cancer centers. Under his leadership, this network has strengthened its synergies, promoting major advances in knowledge sharing and care optimization. At the same time, he exerts a significant influence on the European scene as director of public policy of the European Society of Medical Oncology (ESMO) for the 2023-2024 term. This strategic position allows him to contribute to the development of recommendations and policies that shape the future of oncology on a continental scale.
A vision for the future of the fight against cancer
This new mandate marks an important step in the development of the Léon Bérard Center. Jean-Yves Blay plans to pursue ambitious projects aimed at strengthening research, improving access to therapeutic innovations and developing even more personalized medicine. In a context where cancer remains one of the greatest global health challenges, its role is crucial in advancing research while placing patients at the center of concerns. Through his leadership, he strives to reduce inequalities in access to care and to promote a multidisciplinary approach, which integrates basic research, clinical trials and high-quality care.
A pillar of Lyon and regional excellence
The Léon Bérard Center, under the direction of Jean-Yves Blay, is a driving force behind the scientific and medical attractiveness of the Auvergne-Rhône-Alpes region. Thanks to partnerships with public and private actors, it contributes to making Lyon a stronghold for biomedical research. The renewal of this mandate is a recognition of the results obtained, but also an encouragement to continue efforts in a constantly evolving field. By combining visionary leadership and scientific expertise, Jean-Yves Blay embodies an inspiring model for health and research professionals.
Conclusion: a journey that inspires confidence and hope
Through his third mandate at the Léon Bérard Center, Jean-Yves Blay continues to establish himself as a key figure in the fight against cancer. His commitment, his achievements and his ability to inspire medical and scientific teams make him a valuable asset for the future of oncology. This renewal of mandate is much more than an administrative formality: it symbolizes recognition of past efforts and confidence in future projects. As public health challenges continue to grow, leaders like Jean-Yves Blay are showing that it is possible to combine scientific excellence and human commitment to improve the lives of patients and their families.
